INS Stock Overview
Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Instem plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£8.30 |
| 52 Week High | UK£8.36 |
| 52 Week Low | UK£5.80 |
| Beta | 0.42 |
| 1 Month Change | 9.93% |
| 3 Month Change | 40.08% |
| 1 Year Change | 23.88% |
| 3 Year Change | 90.80% |
| 5 Year Change | 244.40% |
| Change since IPO | 348.65% |
Recent News & Updates
Recent updates
Here's Why We Think Instem (LON:INS) Might Deserve Your Attention Today
Oct 14
An Intrinsic Calculation For Instem plc (LON:INS) Suggests It's 29% Undervalued
Aug 31Instem plc (LON:INS) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jan 25Instem plc's (LON:INS) Intrinsic Value Is Potentially 44% Above Its Share Price
Sep 04Is Instem plc's (LON:INS) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 03Shareholders Are Thrilled That The Instem (LON:INS) Share Price Increased 190%
Jan 29Calculating The Intrinsic Value Of Instem plc (LON:INS)
Dec 25Shareholder Returns
| INS | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | 0.3% | -2.6% | 1.1% |
| 1Y | 23.9% | 32.8% | 1.9% |
Return vs Industry: INS exceeded the UK Healthcare Services industry which returned -3.1% over the past year.
Return vs Market: INS exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| INS volatility | |
|---|---|
| INS Average Weekly Movement | 11.8% |
| Healthcare Services Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: INS's share price has been volatile over the past 3 months.
Volatility Over Time: INS's weekly volatility has increased from 6% to 12% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 500 | Phil Reason | www.instem.com |
Instem plc, together with its subsidiaries, provides information technology solutions and services to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution.
Instem plc Fundamentals Summary
| INS fundamental statistics | |
|---|---|
| Market cap | UK£199.64m |
| Earnings (TTM) | UK£3.34m |
| Revenue (TTM) | UK£61.63m |
59.8x
P/E Ratio3.2x
P/S RatioIs INS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INS income statement (TTM) | |
|---|---|
| Revenue | UK£61.63m |
| Cost of Revenue | UK£38.23m |
| Gross Profit | UK£23.40m |
| Other Expenses | UK£20.06m |
| Earnings | UK£3.34m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 37.97% |
| Net Profit Margin | 5.41% |
| Debt/Equity Ratio | 1.9% |
How did INS perform over the long term?
See historical performance and comparison